List of Medical Device Companies in Denmark - 3

Innovations that make a difference Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. In the past, we provided a way to maintain or restore breathing in any environment with the world's first self-inflating resuscitator, the Ambu® Bag™, which is still in use today. More recently, we responded to a need for an endoscopy solution that is always available. The result? Ambu® aScope™, the world's first sterile, single-use flexible endoscope. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America and the Asia Pacific, 4,500+ team members keep Ambu moving forward. Ambu – Forever Forward For more information, please visit www.ambu.com

MedTrace is striving to minimize diagnostic uncertainty through better perfusion imaging. Perfusion imaging provides medical professionals with a functional understanding of the organs blood supply inside the patient. MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly. Our solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for non-invasive blood flow quantification. Our innovative solution is intended to making 15O-water practically available right next to the PET scanner connected to an onsite cyclotron, with a software package to quantify the myocardial blood flow and perfusion. IMPORTANT NOTICE: MedTrace's products are not currently cleared for routine use in any markets, including both the US and Europe. In the US, 15O-water is currently under investigation as an investigational drug in a Phase 3 clinical trial. In Europe, its use is in compliance with approvals granted by national drug authorities, in accordance with the specific legislation of each member state.

Demant is a world-leading hearing healthcare and technology group built on a heritage of care, health and innovation since 1904. The Group offers solutions and services to help people connect and communicate with the world around them. For more than a century, the Demant Group has played a vital part in developing innovative technologies and gathering know-how to help improve people's hearing and health. In every aspect, from providing hearing care to delivering hearing aids, hearing implants and diagnostic equipment and services to hearing care professionals and users all over the world, Demant is active and engaged. And with the Group's many years of experience with audio and hearing technology, Demant has evolved into a growing business within premium audio and video solutions for enterprises and gaming. The Demant Group operates in a global market with subsidiaries in more than 30 countries, employs more than 20,000 employees and generates an annual revenue of more than DKK 19 billion. Our products are sold in more than 130 countries where we create life-changing differences through hearing health. Listed on Nasdaq Copenhagen stock exchange, Demant is the parent company behind world-renowned and commercially successful brands as Oticon, Bernafon, Sonic, Philips Hearing Solutions, Audika, Oticon Medical, MAICO, Interacoustics, Amplivox, Grason-Stadler, MedRx, Audioscan and EPOS. The William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks. If you want to know how we process your personal data on social media platforms, visit this site: https://www.demant.com/privacy-notice#some